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Abstract  
BACKGROUND: The main prognostic factor in early staged breast cancer is the axillary lymph 
node metastatic affection. Sentinel lymph node biopsy, as a staging modality, significantly 
decreases surgical morbidity. The status of internal mammary lymph nodes gains an increased 
predictive role in grading breast carcinomas and modulation of postoperative therapeutic protocols. 
If positive, almost always are associated with worse disease outcome. Nevertheless, the clinical 
significance of internal mammary lymph node micrometastases has not been up to date precisely 
defined.   
AIM: To present a case of female patient clinically diagnosed as T1, N0, M0 (clinical TNM) ductal 
breast carcinoma with scintigraphic detection of internal mammary and axillary sentinel lymph 
nodes. 
METHODS:  Dual method of scintigraphic sentinel lymph node detection using 99mTc-SENTI-
SCINT and blue dye injection, intraoperative gamma probe detection, radioguided surgery and 
intraoperative ex tempore biopsy were used. 
CASE REPORT: We present a case of clinically T1, N0, M0 ductal breast cancer with scintigraphic 
detection of internal mammary and axillary sentinel lymph nodes. Intraoperative ex tempore biopsy 
revealed micrometastases in the internal mammary node and no metastatic involvement of the 
axillary sentinel lymph node.  
CONCLUSION: Detection of internal mammary lymph node metastases improves N (nodal) 
grading of breast cancer by selecting a high risk subgroup of patients that require adjuvant 
hormone therapy, chemotherapy and/or radiotherapy. 
                                                      
 
 
 
 
 
Introduction 
 
Sentinel lymph nodes (SLN) are the first 
nodes of the lymphatic drainage pathway of malignant 
tumors, hence the first nodes in which cancerous cells 
could spread after they leave the primary tumor and 
enter the lymphatics. SLN detection and intraoperative 
ex tempore pathohistological evaluation, with high 
sensitivity and specificity, provide valid information 
about the tumor’s lymphatic spread (metastases / 
micrometastases) and enables mapping of the tumor’s 
lymphatic drainage. It also determines the type and 
extensity of the surgical intervention – conserving or 
radical mastectomy / lymphadenectomy. If SLN are 
free of micrometastases on ex tempore evaluation, 
sentinel lymph node biopsy (only the SLN removal) is 
performed. But, if metastases are detected, nodal up 
staging (from N0 to N1) is obligatory and radical 
lymphadenectomy is performed. Axillary lymph node 
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status is the most important prognostic factor in breast 
cancer patients. The technique for SLN detection, 
extirpation and ex tempore evaluation is a minimally 
invasive operative procedure, but at the same time a 
highly precise evaluation method, for axillary lymph 
node metastatic involvement. The literature data 
indicates that this technique could be considered as a 
successful alternative to the conventional radical 
axillary lymph node dissection [1, 2].  
Lately, the status of internal mammary lymph 
nodes increases its predictive role in breast carcinoma 
grading and modification of the postoperative 
therapeutic protocols [3]. If positive, they are almost 
always associated with worse disease outcome and 
therapeutic protocol redefinition [4]. Nevertheless, 
visualisation of the internal mammary lymph nodes 
with the method of SLN detection is rare, in only 20% 
of the cases, and the clinical significance of 
micrometastases in this lymphatic drainage pathway 
has not yet been precisely defined [5]. 
 The aim of this study was to present a case of 
female patient clinically diagnosed as T1, N0, M0 
(clinical TNM) ductal breast carcinoma with 
scintigraphic detection of internal mammary and 
axillary sentinel lymph nodes. 
 
 
Material and Methods 
 
The scintigraphic SLN detection included 
preoperative subcutaneous application (16 h prior the 
surgical procedure) of 4mCi (150 MBq) 99mTc-
SENTI-SCINT, subdivided in 4 separate doses (each 
dose of 1 mCi/37MBq respectively) injected into 4 
separate periareolar locations. Considering the fact 
that radiotracers were used, we followed the ALARA 
principles (as low as reasonably achievable) in order 
to obtain the best diagnostic presentation with the 
minimum radiation burden to the patient.  
SENTI-SCINT is a MEDI-RADIOPHARMA 
LTD Hungary commercial kit, composed of human 
serum albumin nano-sized colloid particles with 
diameter of 100-600 nm in a form of sterile lyophilised 
powder. The particles were labelled with 99mTc-
pertechnetate.  
Quality control of the radiolabeled tracer was 
performed with ascendant paper chromatography. 
The injected volume at single site did not exceed 0.2-
0.3 ml, and it was extremely important to avoid the 
blood vessels during the application. In case of 
intravascular application, the SLN detection procedure 
is considered unsuccessful. 
Post injection, we performed dynamic 
acquisition (30 minutes; 30 frames, 60 seconds per 
frame, 256 x 256 matrix) followed by static AP, AL 
(lateral) and AO (oblique) positions (300 seconds per 
position) 30 min, 1 h, 2 h and 16 h post injection, 
using the dual head gamma camera Mediso DHV 
Nucline Spirit. We used cobalt source Featherlite 
Co57 flood source MED 3709 for body contour 
drawing, and the SLN detection was performed with 
gamma detection probe EUROPROBE SYSTEM CE 
0459. Preoperatively we used gamma probe to detect 
the SLN location, quantify and mark the skin site 
above it in 2 positions AP and AL/AO in order to help 
the surgeon to determine the best operation incision 
approach for minimally invasive surgical procedure. 
Intraoperatively, the gamma probe was used for 
radioguided surgery, activity quantification of the 
extirpated SLN and possible additional SLN or 
remnant detection. 
The sensitivity and specificity of the SLN 
detection method was increased with the use of sterile 
solution of metilen blue dye (vital blue) 0.5-1 ml, 
injected intradermally 15 min before the operative 
procedure. 
The histopathological evaluation of the 
extirpated SLN was performed by routine hematoxylin 
and eosin (H & E) staining and immunohistochemistry 
section analyses. 
 
 
Case Report 
 
We present a case of a 48 years old female 
patient clinically diagnosed as T1, N0, M0 (clinical 
TNM) ductal breast carcinoma. The patient underwent 
diagnostic mammography (27.03.2013) and the 
results presented mastopathy with diffuse 
monomorphic calcifications. No pathological findings 
were detected (ACR type 4; BIRADS 2). 
Ultrasonography was performed the next day and it 
revealed a 1 cm hypoechoic formation, without 
pathological vascularization, in the left breast, in the 
lower medial quadrant, parasternal (BIRADS 4). There 
were no enlarged axillary lymph nodes on palpation or 
ultrasonography. Core biopsy was performed 
(29.03.2013) that showed presence of ductal breast 
carcinoma. The patient was admitted to our Institute 
(3.04.2013) for scintigraphic SLN detection. We used 
the dual method of scintigraphic SLN detection using 
99mTc-SENTI-SCINT and blue dye injection. 
The results revealed double drainage of the 
radiotracer, primary towards the intramammary lymph 
nodes and secondary towards the axillary lymph 
nodes. We were able to detect 2 SLN, the first one in 
the region of a. mammaria interna and the second one 
in the axillary region. (Fig. 1 and Fig. 2) Drainage of 
the blue dye was towards the internal mammary 
region and no drainage towards the axillary region 
was observed.  
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Figure 1: Dual method of scintigraphic SLN detection using 99mTc-
SENTI-SCINT and blue dye injection - AP position 2 h post 
injection. 
 
Radioguided surgical procedure was 
performed and both SLN, the internal mammary and 
the one in the axillary region, were extirpated. Ex 
tempore pathohistological analysis presented no 
micrometastases in the axillary SLN and 
micrometastases > 0.2 mm in the internal mammary 
SLN. The final postoperative histopathological 
evaluation confirmed these results and the 
 immunohistochemical findings presented ER+, PR-, 
HER2+. Taking this into consideration, and also the 
negative tumor markers, negative ultrasonography 
results and negative bone scan results, the 
postoperative TNM classification was pT1 N1b M0. 
The operative procedure included sentinel lymph node 
biopsy of both axillar lymph node and lymph node 
around arteria mamaria interna and quadrantectomy, 
without radical axillary lymphadenectomy, considering 
the fact that the SLN in the axillary region was 
negative on ex tempore pathohistological 
examination. Since the internal mammary SLN was 
positive for micrometastases, the patient was admitted 
to the University Clinic of Radiotherapy and Oncology 
for adjuvant treatment. 
 
Figure 2: Dual method of scintigraphic SLN detection using 99mTc-
SENTI-SCINT and blue dye injection - AP position 16 h post 
injection. 
Discussion 
 
SLN detection technique was developed for 
precise diagnosis of micrometastases in the axillary 
lymph nodes in breast cancer patients with clinically 
and ultrasonographically negative lymph nodes 
staged as T1-2 N0 M0 [1, 6]. In the last years, the 
status of the internal mammary lymph nodes 
increases its predictive role in N (nodal) breast 
carcinoma grading and postoperative therapeutic 
protocols modification. The interest for this lymphatic 
pathway dates many years before the introduction of 
lymphoscintigraphy and SLN detection methods, 
when during the extended radical Halsted mastectomy 
the intramammary lymph nodes had also been 
extirpated and histopathologically analysed [7, 8]. This 
radical type of mastectomy enabled the first insight in 
the internal mammary lymphatic pathways and those 
first results also indicated that if positive for 
metastases, this lymph nodes correlate with worse 
disease outcome, more aggressive carcinoma 
variants and lower survival rate [9-11].   
Internal mammary lymph nodes are visualised 
in 20% of the cases in which SLN detection method 
has been applied. Shen et al. in their study point out 
the fact that metastatically positive internal mammary 
lymph nodes are an independent factor for the 
decrease in survival rate [5]. Guth et al. and Hogan et 
al. in two independent research studies conclude that 
patients with positive internal mammary lymph nodes 
have more aggressive tumours, with higher rate of 
lymphovascular invasion and axillary metastases [4, 
12]. 
Patients diagnosed with positive internal 
mammary lymph nodes and negative axillary lymph 
nodes, have similar 10 years survival rate, 
approximately 60%, as patients with positive axillary 
lymph nodes [6, 11]. This fact favours the necessity of 
internal mammary lymph node detection and one 
should always have in mind the possible drainage 
towards these lymphatic pathways in order not to 
avoid a high risk subgroup of patients with axillary 
negative and possible internal mammary positive 
lymph nodes.  
Up to date clinical research trials consider the 
postoperative systemic adjuvant chemo and 
radiotherapy as an option in this subgroup of patients 
[13]. Effects of radiotherapy on survival rate in 
patients with positive internal mammary lymph nodes 
are subject of a large clinical trial (EORTC 22922). 
Considering the results of this study, patient selection 
for adjuvant radiotherapy should be based on a 
diagnosis of positive internal mammary lymph nodes 
with SLN detection method. In this manner, the 
diagnosis of positive internal mammary lymph nodes 
improves the N grading of breast carcinomas. 
The dilemma if the positive internal mammary 
lymph nodes correlate with the status of the axillary 
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lymph nodes is current clinical scientific issue. In our 
case both internal mammary and axillary SLNs were 
detected, the axillary being negative on ex tempore 
histopathology analysis, and the internal mammary 
being positive. 
Previous scientific research in this field 
indicates different combinations of metastatic 
involvement in both lymphatic pathways: negative 
internal mammary and negative axillary, positive 
internal mammary and negative axillary and positive 
internal mammary and positive axillary lymph nodes 
(Table 1). 
Table 1: Published papers about sentinel lymph nodes. 
 
References 
 
Patients with 
ISLN 
Negative ISLN 
Negative 
ASLN 
Positivei ISLN 
Negative 
ASLN 
Positive ISLN 
Positive ASLN 
Intra et al., 2009 [14] 15 9 6  
Kijima et al., 2008 [15] 4 2 2  
Mathelin et al., 2005 [16] 2 1 1  
Tytle et al., 2003 [17]  1   1 
Gajdos et al., 2001 [18] 1   1 
 
ISLN - intramammary sentinel lymph nodes; ASLN - axillary sentinel lymph nodes. 
  
Up to date, no case of negative ISLN and 
positive ASLN has been reported in the literature. This 
fact raises the dilemma of possible primary breast 
carcinoma drainage towards the internal mammary 
lymph nodes and remains as a scientific challenge in 
future. In this context, Vijan et al. in their scientific 
research conclude that patients with positive ISLN 
have high incidence of axillary metastatic involvement 
and they raise a hypothesis about internal mammary 
lymph nodes being "sentinel nodes" for the axillary 
lymph nodes [19].  
According to the scientific data, if internal 
mammary lymph nodes are positive and axillary 
nodes are negative, radical axillary dissection could 
be avoided. The extent of the surgical procedure 
concerning the axilla should be based only on the 
status of the axillary lymph nodes [20].  
In conclusion, the clinical significance of the 
positive internal mammary sentinel lymph nodes has 
not yet been clearly and precisely defined. Further 
detailed analysis on larger scale case series will 
contribute to solving this clinical issue. Up to date, we 
can conclude that the diagnosis of the ISLN improves 
N breast carcinoma grading by detecting a subgroup 
of high risk patients that require adequate 
postoperative adjuvant chemo and radiotherapy. The 
clinical decision for the surgical treatment of the axilla 
should be based solely on the axillary lymph node 
status even if the internal mammary nodes are 
positive for metastases. 
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